Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford is delighted to announce a joint gift from the Eurofins Foundation and SENSE Foundation Brussels to support students in the Medical Sciences and Mathematical, Physical and Life Sciences Divisions. The donation will lead to the creation of Eurofins Awards for undergraduate and postgraduate students, which will be granted over the course of the next three years.

© John Cairns
Analysing volatile samples using a Gas Chromatography Mass Spectronomy System

The Eurofins Awards will provide students with the opportunity to travel overseas for field trips, research or training, and will also support dissertation writing costs. This will enable more students to undertake extra-curricular activities that will enhance their studies and benefit them as they take the first steps in their professional lives. The awards will be made available to academically outstanding students who would not otherwise be able undertake such activities.

Professor Robert Gilbert, Director of the Graduate School in the Medical Sciences Division, says: ‘We are extremely grateful to the Eurofins Foundation and SENSE Foundation Brussels for their support of students in the Medical Sciences. These awards will help our students gain valuable, additional experience to support their professional development and ensure that they make the most of all opportunities whilst studying here.’

Read more on the University of Oxford's Development Office website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.